← Human Trials & Peer-Reviewed Studies
Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.
Plain-language guide to PMID 28376103 (2017): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 80 patients.
Key Facts
- PMID
- 28376103
- Journal
- PloS one
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Komolmit P et al. (7 authors)
- DOI
- 10.1371/journal.pone.0174608
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
Vitamin D deficiency was common among patients with chronic hepatitis C (CHC) and had negative influence on treatment outcome.
Interferon gamma-induced protein 10 (IP-10) and enzyme dipeptidyl peptidase-4 (DPP IV) involved in inflammatory responses in CHC.
Who Took Part
According to the abstract, 80 patients were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
The levels of 25-hydroxyvitamin D [25(OH)D], Th1/Th2 cytokines, IP-10 and DPP IV were measured at baseline and at the 6th week.
What Was Measured
Vitamin D deficiency was common among patients with chronic hepatitis C (CHC) and had negative influence on treatment outcome.
Their higher levels at pretreatment of CHC could predict poorer responses.
PubMed files the paper under topics including Biomarkers, Chemokine CXCL10, Cytokines, Dipeptidyl Peptidase 4, Ergocalciferols, Hepatitis C, Chronic and Vitamin D Deficiency.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 80 patients.
The publication is from 2017 (PloS one), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.